Nobuaki Kobayashi

35PUBLICATIONS
17CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Nov 27, 2025
The miR-200 Family in Non-Small-Cell Lung Cancer: Molecular Mechanisms, Clinical Applications, and Therapeutic Implications.

Nobuaki Kobayashi, Yukihito Kajita, Fangfei Yang

|Aug 13, 2025
Real-world efficacy of immune checkpoint inhibitors in PD-L1 negative non-small cell lung cancer: a multicenter retrospective study.

Suguru Muraoka, Nobuaki Kobayashi, Ayami Kaneko

|Aug 13, 2025
MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer.

Ayami Kaneko, Nobuaki Kobayashi, Sousuke Kubo

|Mar 21, 2025
Rapid detection of non-small cell lung cancer driver mutations using droplet digital polymerase chain reaction analysis of bronchial washings: a prospective multicenter study.

Kohei Somekawa, Nobuaki Kobayashi, Satoshi Nagaoka

|Jan 08, 2025
The Impact of Bevacizumab and miR200c on EMT and EGFR-TKI Resistance in EGFR-Mutant Lung Cancer Organoids.

Nobuaki Kobayashi, Seigo Katakura, Nobuhiko Fukuda

|Aug 01, 2024
High red blood cell distribution width attenuates the effectiveness of Immune checkpoint inhibitor therapy: An exploratory study using a clinical data warehouse.

Hiromi Matsumoto, Taichi Fukushima, Nobuaki Kobayashi

Pageof 6

Frequent Collaborators

13 joint publications

Nobuyuki Horita

10 joint publications

Yu Hara

7 joint publications

Masaki Yamamoto

6 joint publications

Keisuke Watanabe